Health Condition 1: K928- Other specified diseases of the digestive system
Conditions
Interventions
Intervention1: Itolizumab: Dose:
Treatment Period 1
140 mg (1.4mL) SC every two weeks starting from Day 1 then Week 2, 4, 6, 8, 10
Treatment Period 2
140 mg (1.4mL) SC every two weeks on Week 12,
Sponsors
Biocon Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1.Male or female, 18 years of age or older with diagnosis of moderate to severe active UC confirmed by endoscopy and histologic evidence at least 6 months prior to screening visit, as defined by a Mayo score 2.Patients naïve to biologic therapy (e.g., TNF antagonist) and have a prior OR current UC medication history. 3.Before the first administration of study drug, the following conditions must be met a.If receiving conventional immunomodulators (i.e., 6-MP or Azathioprine), must have been taking them for =12 weeks, and on a stable dose for at least 4 weeks. 4.A female patient has been sterilized or has been menopausal, or the patient has no pregnancy plan during the trial and voluntarily adopts effective contraceptive measures. 5.Able to comprehend the full nature and purpose of the study, including possible risks and side effects, and able to comply with all requirements of the study. Must be able to understand and voluntarily sign an informed consent prior to any study procedures.
Exclusion criteria
Exclusion criteria: 1.Patient with Crohn Disease, indeterminate colitis microscopic colitis, ischemic colitis, or radiation induced colitis, based on medical history, endoscopy, and or histological findings or presence or history of fistula with Crohn Disease or current evidence of fulminant colitis 2.History of pancolitis for less than or equal to 8 years or left-sided colitis less than or equal to 15 years. 3.Extensive colonic resection or colectomy or imminent risk of colectomy, or prior history of toxic megacolon within 6 months of screening 4.History or current evidence of colonic dysplasia or adenomatous colonic polyps. 5.Active malignancy or carcinoma in situ within the last 5 years 6.Diagnosis of primary sclerosing cholangitis by liver function test. 7.Presence or history of active tuberculosis (TB) or latent TB infection, 8.Known acute or chronic viral hepatitis B or hepatitis C, or human immunodeficiency virus (HIV). 9.Other local or systemic pathological states requiring therapy with corticosteroids within 30 days prior to randomization except inhaled corticosteroids 10.Pregnant or breastfeeding, or positive pregnancy test in a pre-dose examination. 11.Does not agree to use contraception in the event of sexual activity for 130 days after the last dose of study drug if a female of childbearing potential or a male with a partner of childbearing potential. 12.Any serious inherited disorder, medical condition, or abnormality of clinical laboratory tests that, in the investigator judgment, precludes the patient safe participation in and completion of the study. 13.Evident renal disease or insufficiency, estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of participants who achieved clinical remission per Total Mayo ScoreTimepoint: Week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment Period 1 1. Proportion of Participants Who Achieved Clinical Response Per Total Mayo Score. Timepoint: Week 12;2.Proportion of participants who Achieved Mucosal Healing.Timepoint: Week 12;3.Proportion of Participants who achieved endoscopic remission.Timepoint: Week 12;Treatment Period 2 – Participants who were responders at Week 12 1.Proportion who achieved clinical remission per Total Mayo Score.Timepoint: Week 24.;2.Proportion who achieved Mucosal HealingTimepoint: Week 24.;3. Proportion who achieved endoscopic remission.Timepoint: Week 24;Who were non-responders at Week 12 1. Proportion who achieved clinical remission per Total Mayo Score.Timepoint: Week 24;2. Proportion who achieved clinical response per Total Mayo ScoreTimepoint: Week 24;3. Proportion who achieved Mucosal Healing.Timepoint: Week 24;4. Proportion who achieved endoscopic remission.Timepoint: Week 24;5. Proportion who achieved Histologic RemissionTimepoint: Week 24 | — |
Countries
India
Contacts
Public ContactMs Jayanti Panda
Biocon Biologics Limited
Outcome results
None listed